Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance
收藏官方服务：
资源简介：
Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance
应用场景：
创建时间：
2011-03-31
相关数据集
Gene expression profile of patient-derived head and neck squamous carcinoma cells subjected to different treatments.. Gene expression profile of patient-derived head and neck squamous carcinoma cells subjected to different treatments.
In order to investigate the mechanisms underlying response and resistance towards treatment in HNSCC, we used low passage in vitro HNSCC cultures from two patients, namely SJG26 and SJG17. Both cultur
NIAID Data Ecosystem70
Loss of IFN-g signaling in tumor cells associates with primary resistance to anti-CTLA-4 therapy
"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-?,
NIAID Data Ecosystem40
DataSheet9_Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma.ZIP
SHP2 mediates signaling from multiple receptor tyrosine kinases (RTKs) to extracellular signal-regulated kinase (ERK) and Ser and Thr kinase AKT, and its inhibitors offer an unprecedented opportunity
NIAID Data Ecosystem10
Integrative Analyses of Gene Expression and DNA Methylation Profiles in a Breast Cancer Cell Line Model of Tamoxifen-Resistance Indicate a Crucial Role of Cells with Stem-like Properties. Homo sapiens
Purpose: Development of resistance to tamoxifen is an important clinical issue in the treatment of patients with breast cancer. Tamoxifen resistance may be the result of the acquisition of epigenetic
NIAID Data Ecosystem50
Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]. Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]
Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatment. Most current studies have uncovered the alternations of HER2 and assoc
NIAID Data Ecosystem20
